Enduring Materials
Access slide decks and video via the links in the schedule below.
= PDF of slides is available
= Presentation video is available
Program Schedule
Thursday, November 10, 2016
| 8:00 a.m. – 8:05 a.m. | Welcome & Introductions Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey |
Session I: Introduction to Models of Immunotherapy2.0 AMA PRA Category 1 Credits™ |
|
| 8:05 a.m. – 8:35 a.m. | Major Questions Related to Immunotherapies that Require Models to Address Mario Sznol, MD – Yale School of Medicine |
| 8:35 a.m. – 9:05 a.m. | Overview of Mouse-Mouse Models Marcus W. Bosenberg, MD, PhD – Yale School of Medicine |
| 9:05 a.m. – 9:35 a.m. | Overview of Humanized Mice Models A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine |
| 9:35 a.m. – 10:05 a.m. | Overview of Patient-Derived Xenograft (PDX) Models Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey |
Session II: Modeling the Tumor Microenvironment2.0 AMA PRA Category 1 Credits™ |
|
| 10:35 a.m. – 11:05 a.m. | Evaluation of the Tumor Microenvironment Mark B. Headley, PhD – University of California San Francisco |
| 11:05 a.m. – 11:35 a.m. | Factors Affecting Tumor – Microenvironment Interactions Lisa M. Coussens, PhD – Oregon Health and Sciences University |
| 11:35 a.m. – 12:05 p.m. | Vascular Regulation of the Tumor Microenvironment and Immune Responses Amanda Lund, PhD – Oregon Health & Science University |
| 12:05 p.m. – 12:35 p.m. | Components of the Tumor Microenvironment that Module Tumor Immune Responses Kwok-Kin Wong, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School |
Session III: Modeling Evaluation of Immune Therapies1.75 AMA PRA Category 1 Credits™ |
|
| 1:25 p.m. – 2:00 p.m. | Evaluation of Immune Checkpoint Inhibitors in Mice Arlene H. Sharpe, MD, PhD – Harvard Medical School |
| 2:00 p.m. – 2:35 p.m. | Reevaluating the Role of IDO1 in Brain Cancer; Humanized Immunocompetent Mice Take Center Stage Derek A. Wainwright, PhD – Northwestern University |
| 2:35 p.m. – 3:10 p.m. | Developing New Immunotherapies in Preclinical Models and Humans Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University |
| 3:10 p.m. – 3:45 p.m. | What Information Provided by Models will Inform Immune Drug Development and Use? Philip Gotwals, PhD – Novartis Institutes for BioMedical Research, Inc. |
Session IV: Panel Discussion and Future Directions
|
|
| 4:05 p.m. – 4:45 p.m. | Future Directions for the Development and Use of Cancer Immune Models Panelists: Lisa M. Coussens, PhD – Oregon Health and Sciences University Philip Gotwals, PhD – Novartis Institutes for BioMedical Research, Inc. Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine Arlene H. Sharpe, PhD – Harvard Medical School Mario Sznol, MD – Yale School of Medicine Kwok-Kin Wong, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey |
| 4:45 p.m. – 5:00 p.m. | Closing Remarks Marcus W. Bosenberg, MD, PhD – Yale School of Medicine |
Important Dates
Regular Abstracts Published in JITC
November 8, 2016
Late-Breaking Abstracts Published in JITC
December 8, 2016
Thank You, Supporters!
Thank you, SITC 2016 supporters. Because of your generosity, SITC 2016 was a great success!
Interested in supporting other SITC programs? Confirm your support today!
Connect with SITC!